SAMSARA BIOCAPITAL LLC
Q2 2026 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001744967
· CRD 288114
· SEC-registered investment adviser
$1.2B Reported Value Total
SAMSARA BIOCAPITAL, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $2,170,095,404, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $2.3B gross asset value
Venture Capital Fund: $2.3B
Source: Form ADV filed 2026-06-26
Reported value
$1.2B
Quarter over quarter
+10.6%
Holdings
24
Top-10 concentration
90.5%
Key People
Form ADV owners & control persons
Srinivas Akkaraju
MANAGER OF SAMSARA BIOCAPITAL, LLC
Patrick Michael Dominguez
CHIEF COMPLIANCE OFFICER
Michael Philip Dybbs
PARTNER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $1.2B |
| Positions | 24 |
| Change in reported value | +18.3% |
| New positions | 4 |
| Exited positions | 2 |
| Position turnover | 23.1% |
| Top-10 concentration | 90.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
24 | $1.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
22 | $1.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
21 | $969.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
27 | $765.9M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $488.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
37 | $560.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
43 | $728.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
42 | $520.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
40 | $477.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
39 | $646.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
41 | $642.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
41 | $326.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
47 | $569.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
56 | $483.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
54 | $464.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
55 | $428.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
56 | $375.1M |
|
Q1 2022 13F
Filed May 16, 2022
|
56 | $397.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
49 | $515.5M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
46 | $637.3M |
11 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SRRK SCHOLAR ROCK HLDG CORP | $379.4M | 31.16% |
| 2 | ALMS ALUMIS INC | $178.6M | 14.67% |
| 3 | MLYS MINERALYS THERAPEUTICS INC | $158.4M | 13.01% |
| 4 | SEPN SEPTERNA INC | $105.5M | 8.66% |
| 5 | ALMR ALAMAR BIOSCIENCES INC | $67.2M | 5.52% |
| 6 | NGNE NEUROGENE INC | $54.0M | 4.44% |
| 7 | KLRS KALARIS THERAPEUTICS INC | $52.4M | 4.31% |
| 8 | SGP SPYGLASS PHARMA INC | $47.0M | 3.86% |
| 9 | STRO SUTRO BIOPHARMA INC | $35.3M | 2.9% |
| 10 | IVA INVENTIVA SA | $23.9M | 1.96% |
| 11 | JBIO JADE BIOSCIENCES INC | $16.4M | 1.34% |
| 12 | PBLS PARABILIS MEDICINES INC | $15.2M | 1.25% |
| 13 | VTVT VTV THERAPEUTICS INC | $11.2M | 0.92% |
| 14 | AQST AQUESTIVE THERAPEUTICS INC | $10.4M | 0.85% |
| 15 | NKTX NKARTA INC | $9.9M | 0.82% |
| 16 | ARTV ARTIVA BIOTHERAPEUTICS INC | $9.3M | 0.76% |
| 17 | RANI RANI THERAPEUTICS HLDGS INC | $7.9M | 0.65% |
| 18 | AGMB AGOMAB THERAPEUTICS NV | $7.8M | 0.64% |
| 19 | ABVX ABIVAX SA | $7.3M | 0.6% |
| 20 | XFOR X4 PHARMACEUTICALS INC | $6.5M | 0.54% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.